Inloggad som:
CA0881007-Myelom
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
CA0881007-Myelom
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5Ddirected CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomiderefractory Multiple Myeloma
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5Ddirected CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomiderefractory Multiple Myeloma
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast: (2025-07-31)